Good morning :)
Place Order
Add to Watchlist

Piramal Pharma Ltd

PPLPHARMA

Piramal Pharma Ltd

PPLPHARMA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹16,988 cr, stock is ranked 326
High RiskStock is 3.75x as volatile as Nifty
128.905.35% (+6.55)
128.905.35% (+6.55)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹16,988 cr, stock is ranked 326
High RiskStock is 3.75x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹16,988 cr, stock is ranked 326
High RiskStock is 3.75x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-509.552.51
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.915.950.56%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 4 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Piramal Pharma Ltd is a manufacturer of pharmaceutical preparation. It offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 14 global facilities and a global distribution network in over 100 countries. The Company is located in Mumbai, India.

Investor Presentation

View older 

Aug 3, 2023

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2021FY 2022FY 2023TTM
Total Revenue6,544.486,893.937,360.998,011.12
Raw Materialssubtract2,111.852,396.032,634.666,797.05
Power & Fuel Costsubtract136.70163.56207.81
Employee Costsubtract1,467.741,588.831,896.35
Selling & Administrative Expensessubtract709.63868.15949.35
Operating & Other expensessubtract461.02607.95772.10
Depreciation/Amortizationsubtract545.04586.18676.69728.85
Interest & Other Itemssubtract163.45198.25344.18438.52
Taxes & Other Itemssubtract114.02109.0266.3180.04
EPS8.203.37-1.53-0.27
DPS0.000.550.000.00
Payout ratio0.000.160.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2023

Annual report

PDF

Investor Presentation

May 24PDF
May 24PDF
Jan 5PDF
FY 2024

Annual Report Pending

Investor Presentation

Aug 3PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Piramal Pharma Ltd-91.112.51
Sun Pharmaceutical Industries Ltd45.896.560.71%
Cipla Ltd43.135.100.57%
Dr Reddy's Laboratories Ltd22.754.400.65%

Price Comparison

Compare PPLPHARMA with any stock or ETF
Compare PPLPHARMA with any stock or ETF
PPLPHARMA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.14%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding35.02%6.28%3.40%32.51%22.79%

Jun 2023

Aug 2023

Sep 2023

Dec 2023

Shareholding History

Dec '22MarJunAugSepDec '2341.29%39.27%35.01%32.23%32.37%32.51%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 2.48%

Top 5 Mutual Funds holding Piramal Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Flexi Cap Fund - Growth - Direct Plan

Growth
2.5073%0.89%0.89%35/52 (+17)
HDFC Focused 30 Fund - Growth - Direct Plan

Growth
1.1646%1.99%0.27%20/34 (+2)
ICICI PRUDENTIAL VALUE DISCOVERY FUND - DIRECT PLAN - GROWTH

Growth
0.7452%0.32%-0.13%75/101 (-10)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time

News & Opinions

Hmm, looks like data is unavailable here. Please come back after some time.